mRNA 합성용 원료 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

mRNA Synthesis Raw Materials Market Growth & Trends:

The global mRNA synthesis raw materials market size is projected to reach USD 1.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.85% from 2024 to 2030. The major factors driving the market growth include growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research. In addition, the increasing therapeutic applications of RNA technology are projected to offer lucrative opportunities for the mRNA synthesis raw materials market during the forecast period.

The COVID-19 pandemic has increased the demand for mRNA synthesis raw materials for developing an efficient vaccine to battle infectious diseases. mRNA vaccines are a safe and efficient method for preventing COVID-19. In addition, the advantages associated with the mRNA COVID-19 vaccines have sparked the attention of pharmaceutical businesses in delivering vaccines swiftly across the globe. For instance, the National Institute of Allergy and Infectious Diseases and Moderna, Inc. mutually developed the mRNA-1273 (NIAID) in March 2020. As a result, the usage of mRNA vaccines increased significantly during the COVID-19 pandemic.

Furthermore, many major pharmaceutical firms have started working on mRNA-based therapeutics, including Novartis, Alexion, AstraZeneca, Pfizer, Sanofi Pasteur, and Shire. For instance, in January 2022, according to a development and option agreement between Pfizer Inc. and Acuitas Therapeutics, Pfizer will have the option to license Acuitas' LNP technology for up to 10 targets for the development of mRNA therapeutics & vaccines. Therefore, the adoption rate of mRNA synthesis raw materials has increased among pharma & biotech companies, which further fuels the market growth.

Moreover, due to the temporary nature of mRNA translation and lack of integration of the foreign material into the cell's genome, the resulting cellular therapeutic product has a number of benefits over the one obtained by a more conventional approach. Some of the advantages include easier production under acceptable manufacturing procedures, reduced cytotoxicity from on-target off-tumor effects, and better clinical validation and regulatory treatment. Thus, such advantages are expected to increase the demand for mRNA therapeutics and further boost market growth.

Additionally, regarding the treatment and prevention of several diseases, mRNA-based technologies have been proven to be incredibly promising. Tremendous advances in technology and scientific study over the past ten years have made mRNA a feasible therapeutic option, eliminating some of the problems with its use, such as its brief half-life and innate immunogenicity. For instance, as mRNA technology advances, its fusion with new adoptive immunotherapies may result in safer and more efficient methods, such as the creation of cutting-edge chimeric antigen receptor T-cells. Therefore, advancements in mRNA technology are projected to open new avenues for market growth.

However, the high cost of raw materials may impede the market during the study period. For instance, the purchase price of raw materials, such as CleanCap AG, accounts for around 45% of the total raw material costs incurred while producing both vaccines. In addition, the regulatory framework pertaining to approval processes has always been the most critical restraining factor in the biotechnology, pharmaceutical, and medical technology industry. The absence of effective regulatory framework/guidelines for the therapeutic sector in developing countries such as China and India, where the mRNA synthesis raw materials market holds great growth potential due to the presence of a large patient base, is anticipated to impede the market growth in the coming years.

mRNA Synthesis Raw Materials Market Report Highlights:

• The capping agents segment held the largest share of 39.17% in 2023 owing to the advancements in the capping technology and their applications in the biopharma industry and research
• By application, The vaccine production segment dominated the global industry with the largest revenue share in 2023. This can be attributed to the rapid production of mRNA vaccines compared to the conventional vaccines that utilize cell-culture-based production paths, which are often prone to failure.
• North America dominated the global industry in 2023 and accounted for the largest share of more than 36.77% of the overall revenue in 2023, and is expected to grow at the highest CAGR over the forecast period.
• The biopharmaceutical and pharmaceutical companies segment dominated the market with the highest revenue share in 2023, due to the high commercial success of biopharmaceuticals and rapid growth in demand for therapeutics.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End-use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing academic and industrial interest in mRNA technology
    • 3.2.1.2. Advantages of mRNA vaccines
    • 3.2.1.3. Increasing funding for mRNA research
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Nonexistence of effective government regulations for mRNA - based product approvals
    • 3.2.2.2. High cost of mRNA synthesis raw materials
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. mRNA Synthesis Raw Materials Market: Type Business Analysis

• 4.1. Type Segment Dashboard
• 4.2. Global mRNA Synthesis Raw Materials Market Type Movement Analysis
• 4.3. Global mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Capping Agents
  • 4.4.1. Global Capping Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Nucleotides
  • 4.5.1. Global Nucleotides Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Plasmid DNA
  • 4.6.1. Global Plasmid DNA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Global Enzymes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.2. Polymerase
    • 4.7.2.1. Global Polymerase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.3. RNase Inhibitor
    • 4.7.3.1. Global RNase Inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.4. DNase
    • 4.7.4.1. Global DNase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.5. Others
    • 4.7.5.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. mRNA Synthesis Raw Materials Market: Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global mRNA Synthesis Raw Materials Market Application, Movement Analysis
• 5.3. Global mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Therapeutics Production
  • 5.4.1. Global Therapeutics Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Vaccine Production
  • 5.5.1. Global Vaccine ProductionMarket Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. mRNA Synthesis Raw Materials Market: End-use Business Analysis

• 6.1. End-use Segment Dashboard
• 6.2. Global mRNA Synthesis Raw Materials Market End-use Movement Analysis
• 6.3. Global mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 6.4. Biopharmaceutical & Pharmaceutical Companies
  • 6.4.1. Global Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. CROs & CMOs
  • 6.5.1. Global CROs & CMOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Academic & Research Institutions
  • 6.6.1. Global Academic & Research Institutions Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. mRNA Synthesis Raw Materials Market: Regional Estimates & Trend Analysis by Type, Application, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait MRNA Synthesis Raw Materials Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2023
• 8.4. Participant's Overview
  • 8.4.1. F. Hoffmann - La Roche Ltd.
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Jena Bioscience Gmbh
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Merck KGaA
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Yeasen Biotechnology (Shanghai) Co.,Ltd.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. BOC Sciences
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Thermo Fisher Scientific, Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Maravai Lifesciences
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. New England Biolabs
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Creative Biogene
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Hongene
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives